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Significance {#sec1}
============

**Direct tumor-targeting mAbs kill tumors primarily through macrophage-mediated phagocytosis and have demonstrated activity in numerous different cancers. However, these responses are often partial and transient. We now show that the efficacy of these mAbs can be enhanced by increasing the activity and number of macrophages available to phagocytose opsonized tumor cells. This can be achieved indirectly through stimulation of CD27, a costimulatory receptor expressed constitutively on T and NK cells. Activation of these cells triggers the release of chemokines and cytokines that attract and activate macrophages. We describe the unexpected effects of this immunomodulatory mAb and how it can be harnessed to improve the anti-tumor efficacy of direct tumor-targeting antibodies in multiple tumor types.**

Introduction {#sec2}
============

Monoclonal antibodies (mAbs) have proven to be potent tools in cancer treatment (reviewed in [@bib55]). They can be divided into two groups based on their effector functions: direct tumor-targeting mAbs, such as anti-CD20, anti-Her2, and anti-EGFR target the tumor directly through innate effectors, whereas immunomodulatory mAbs (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4, and anti-CD40) activate the adaptive immune system. It is generally agreed that direct-targeting mAbs exert their anti-tumor activity by recruiting FcγR-expressing cellular effectors or by blocking oncogenic signaling ([@bib59], [@bib19], [@bib51], [@bib5]), whereas immunomodulators either remove inhibitory signaling (checkpoint blockers) or directly stimulate immune effector cells (immunostimulatory mAbs). It has previously been shown that, when combined, certain immunomodulatory mAbs (e.g., 4-1BB) can improve the anti-tumor efficacy of direct tumor-targeting mAbs (CD20) ([@bib42]) through enhancement of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) ([@bib18], [@bib30]), which has moved to the clinical setting for validation. Apart from these data, there are few other studies examining the combination of direct tumor-targeting and immunomodulatory mAbs. To this end, we examined whether the anti-tumor efficacy of the archetypal direct-targeting mAb, anti-CD20, could be enhanced by different immunomodulatory mAbs.

CD27 is a member of the tumor necrosis factor receptor (TNFR) superfamily and exists as a type 1 transmembrane, disulfide-linked homodimer ([@bib52]). Unlike other TNFR members, which are only expressed following activation, CD27 is constitutively present on all subsets of T cells ([@bib52]), a subset of NK cells ([@bib43]), and memory B cells ([@bib58]). Upon T cell activation, CD27 expression is further transiently upregulated ([@bib15]). On T cells, the simultaneous engagement of the T cell receptor (TCR) and CD27, such as by its ligand, CD70, is required for its costimulatory effects ([@bib3], [@bib28]). CD70-CD27 interaction leads to recruitment of TNFR-associated factor (TRAF) proteins to the CD27 cytoplasmic tail ([@bib1], [@bib20]). Subsequent activation of canonical and non-canonical nuclear factor-κB (NF-κB) and c-Jun-N-terminal kinase (JNK) signaling pathways follows to elicit cellular responses ([@bib36]) involving CD8^+^ T cell priming, proliferation, survival, and cytotoxicity ([@bib11], [@bib40], [@bib45]). On other cell types, CD70/CD27 interaction supports B cell expansion in the germinal center ([@bib58]). A subset of NK cells also express CD27, and here engagement of CD27 has been shown to increase interferon gamma (IFNγ) secretion, albeit without a concomitant enhancement of NK cytotoxicity ([@bib44]). The anti-tumor effect of CD27 ligation has been demonstrated in murine B cell lymphoma ([@bib16]) and melanoma models ([@bib38]), and preliminary results of the phase I studies of the anti-human CD27 mAb, varlilumab demonstrate that it is well tolerated and has anti-tumor efficacy ([@bib10]).

Results {#sec3}
=======

Combining Anti-CD20 with Most Immunomodulatory mAbs Does Not Result in Robust Improvements in Therapeutic Efficacy {#sec3.1}
------------------------------------------------------------------------------------------------------------------

As an initial screen to investigate whether the therapeutic efficacy of anti-CD20 could be enhanced by combination with immunomodulatory mAbs, we used the syngeneic, immunocompetent murine B cell lymphoma model, BCL~1~ ([@bib41]). Anti-CD20 was tested in combination with mAbs to costimulatory receptors, OX40, 4-1BB, GITR, or checkpoint blockers TIGIT, PD-L1, PD-1, or CTLA-4 ([Figures 1](#fig1){ref-type="fig"}A--1F). Anti-CD20 alone provided a modest survival benefit with a median survival of 29.5 days compared with 21 days with control mice. When anti-CD20 was combined with immunomodulatory reagents, only anti-OX40 provided a modest benefit with a median survival of 45.5 days ([Figure 1](#fig1){ref-type="fig"}A), with the other reagents providing small, non-statistically significant improvements in tumor control. 4-1BB mAb was highly effective as a single agent in this model, with 56% of mice surviving beyond 100 days, but addition of anti-CD20 did not improve its therapeutic efficacy ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Combining Anti-CD20 with Immunomodulatory mAbs in B Cell LymphomaBCL~1~-bearing mice were treated with isotype control, anti-CD20 on day 4 (200 μg) alone, or with: (A) anti-OX40 (250 μg) on days 5 and 9; (B) anti-TIGIT (200 μg) on days 5, 8, and 11; (C) anti-GITR (250 μg) on days 5 and 8; (D) anti-PD-L1 (200 μg) on days 5, 7, 9, 11, and 13; (E) anti-PD-1 (250 μg) on days 5, 7, and 9, or anti-CTLA-4 (100 μg) on days 5, 7, and 9; (F) anti-4-1BB (200 μg) on days 5, 8, and 11. Graphs show n = 10 per group, compiled from two independent experiments. Log-rank test was used to assess p values; ^∗^p \< 0.05, ^∗∗^p \< 0.01.

Anti-CD27 Enhances Direct Tumor-Targeting mAb Therapy {#sec3.2}
-----------------------------------------------------

An agonistic mAb against CD27 was also tested with anti-CD20 in the same model ([Figure 2](#fig2){ref-type="fig"}A). Anti-CD27-treated mice had improved survival compared with control or anti-CD20-treated mice, but, significantly, when given in combination with anti-CD20, 100% of the mice were cured beyond 100 days.Figure 2Anti-CD27 in Combination with a Tumor-Targeting mAb(A) BCL~1~-bearing mice were treated with isotype control, anti-CD20 (200 μg) on day 4, anti-CD27 (100 μg) on days 5--8, or in combination. Graph shows n = 15 per group, representative of three independent experiments.(B) A31-bearing mice were treated with isotype control, anti-CD20 (200 μg) on days 4 and 14, anti-CD27 (100 μg) on days 5--8 and 15--18, or in combination. Graph shows n = 10 per group, compiled from two independent experiments. Data were assessed using log-rank test; ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.(C--E) Eμ-TCL1-bearing mice were treated with anti-CD20 (250 μg) or anti-CD27 (100 μg) the next day, or the combination, \>3 weeks post-tumor inoculation when peripheral tumor was \>10%. Graphs show n = 6/group, representative of two independent experiments. Animal survival (C), peripheral blood tumor burden (D), and total PBMC count (E). Mean and SEM shown. Log-rank test was used in (C) and Mann-Whitney test in (D and E); ^∗∗^p \< 0.01.(F and G) C57BL/6 mice were inoculated with 50,000 B16F10 tumor cells intraperitoneally on day 0, and treated with anti-gp75 (50 μg) on day 0 and anti-CD27 (100 μg) on day 1 (all intraperitoneally). Mice were harvested on day 13, and peritoneal metastases were measured. Representative photographs are shown in (F), with metastases highlighted by the red arrows. The graph in (G) shows data accumulated from two experiments, n = 11--12 mice per group. Mann-Whitney test was used to assess the p value; ^∗∗^p \< 0.01. See also [Figures S1](#mmc1){ref-type="supplementary-material"}.

To ensure that the therapeutic benefit of anti-CD20/CD27 therapy was not confined to the BCL~1~ model, the combination was also tested in the A31 B cell lymphoma ([@bib13]) ([Figure 2](#fig2){ref-type="fig"}B) and Eμ-TCL1, B-chronic lymphocytic leukemia ([@bib7]) models ([Figures 2](#fig2){ref-type="fig"}C--2E). In both models, anti-CD20 alone provided a modest therapeutic benefit. Anti-CD27 alone also improved survival of tumor-bearing mice, particularly in the A31 model. However, in combination, a significant improvement was observed, with all mice surviving beyond 100 days. In the Eμ-TCL1 model, therapy provided by either anti-CD20 or anti-CD27 alone was minimal ([Figures 2](#fig2){ref-type="fig"}C--2E), yet the combination delivered efficient tumor depletion, leading to experimental cures.

We also examined anti-CD27 with another direct tumor-targeting mAb, anti-gp75, in the B16F10 melanoma model ([Figures 2](#fig2){ref-type="fig"}F and 2G), where peritoneal metastases were assessed on day 13 after tumor inoculation ([@bib35]). Anti-gp75 and anti-CD27 individually had some activity in reducing tumor burden but the combination was superior ([Figure 2](#fig2){ref-type="fig"}G).

These investigations demonstrate that agonistic anti-CD27 can improve the anti-tumor efficacy of a tumor-targeting mAb to B cell lymphoma in a way not seen with other immunomodulatory mAbs.

Combination Therapy Is Partly Dependent on T Cells {#sec3.3}
--------------------------------------------------

Subsequent investigations aimed to dissect the mechanism by which anti-CD27 enhances anti-CD20 therapy. First, we examined the expression of CD27 on the B cell tumors examined, alongside potential immune effectors ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Anti-CD27 did not bind to BCL~1~, A31, or Eμ-TCL1, and so is not acting as a direct tumor-targeting mAb. Consistent with previous reports ([@bib43], [@bib52]), CD27 was expressed constitutively on NK cells and all subsets of T cells.

Given that CD27 is a well-described costimulatory receptor on T cells, we examined the effect on T cells in the BCL~1~ model. BCL~1~-bearing mice treated with anti-CD27 and anti-CD20/CD27 had nearly 3-fold more activated CD8^+^ T cells (CD62L^hi^CD44^+^ and CD62L^lo^CD44^+^) in the spleen than control and anti-CD20-treated mice on day 13 ([Figures 3](#fig3){ref-type="fig"}A and 3B). Further, there was a significant increase in the number of CD8^+^ T cells in the anti-CD20/CD27 group compared with anti-CD20 alone (median 13.6 × 10^6^ versus 3.6 × 10^6^, respectively) ([Figure 3](#fig3){ref-type="fig"}C). A marked increase in CD8^+^ T cell count was also observed with anti-CD27 alone (median 15.6 × 10^6^), and this was significantly different compared with the control group (median 8.8 × 10^6^). Increased numbers of regulatory T cells (Tregs) were also observed with anti-CD27- and combination-treated groups. Despite the increase in Tregs, the total CD8^+^/Treg ratio was higher in the combination group compared with anti-CD20 alone (medians 5.9 versus 3.2, respectively).Figure 3Anti-CD27 Stimulation of CD8^+^ T cells(A--C) BCL~1~-bearing mice were treated as described in [Figure 2](#fig2){ref-type="fig"}A, and spleens were harvested on day 13. Cell counts were obtained, and cells were analyzed by flow cytometry. (A) Representative flow cytometry plots showing the percentages of activated CD8^+^ T cells, denoted by CD62L and CD44 expression, upon treatment with either control, anti-CD20, anti-CD27, or in combination. (B) Graphs showing cumulative data from (A), n = 5 per group, medians shown. (C) Graphs show absolute numbers of CD8^+^ T cells, Tregs, and CD8^+^/Treg ratio, n = 7 per group, medians shown, ns indicates not significant. Student's t test was used for (B) and Wilcoxon test for (C) to assess p values; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) BCL~1~-bearing mice were treated as in (A), and spleens were harvested on days 6 and 9 and stained for CD8 by immunohistochemistry. Both scale bars represent 500 μm. Boxed inset enlarged ×3.(E) BCL~1~-bearing mice were depleted of CD8^+^, CD4^+^, or both cell types, and treated as described in [Figure 2](#fig2){ref-type="fig"}A. Graphs show n = 5--10 per group, representative of two independent experiments, ns indicates not significant.(F) BCL~1~-bearing mice were depleted of NK cells and treated with isotype control, anti-CD20, anti-CD27, or the combination. Graphs show n = 5--10, from two independent experiments, ns indicates not significant.(G) BCL~1~-bearing mice were depleted of T and NK cells, and treated with isotype control, anti-CD20, anti-CD27, or the combination. Graphs show n = 5, representative of two independent experiments.Log-rank test was used to assess p values; ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

When the spleens of control and treated BCL~1~-bearing animals were examined on days 6 and 9 by immunohistochemistry, a change was observed in the pattern of CD8 staining ([Figure 3](#fig3){ref-type="fig"}D). In control and anti-CD20 treated mice, CD8^+^ staining was confined to the interfollicular regions. In contrast, in anti-CD27- and combination-treated mice, staining was observed in both the interfollicular and follicular regions on day 6 and throughout the whole spleen on day 9. This demonstrates that anti-CD27 given alone, or in combination with anti-CD20, alters the CD8^+^ T cell distribution.

Altogether, this and published data ([@bib16]) suggest that anti-CD27's anti-tumor effect is in part mediated by CD8^+^ T cells. To directly assess their contribution to the immunotherapy in the BCL~1~ model, we depleted CD4^+^, CD8^+^, or both CD4^+^ and CD8^+^ T cells ([Figure 3](#fig3){ref-type="fig"}E). As expected, deletion of both CD4^+^ and CD8^+^ T cells abrogated anti-CD27 monotherapy. Deletion of either CD4^+^ or CD8^+^ alone had minimal impact, but deletion of both CD4^+^ and CD8^+^ T cells together reduced therapeutic efficacy of the combination therapy, albeit incompletely. This suggests that, while T cells are important, additional mechanisms of tumor killing compensate for the loss of T cell cytotoxicity in the anti-CD20/CD27-treated cohorts.

The Contribution of NK Cells to Anti-CD20/CD27 Combination Therapy {#sec3.4}
------------------------------------------------------------------

The other main population of immune effector cells that express CD27 are NK cells, so we explored the ability of anti-CD27 to activate these cells *in vivo*. Naive wild-type (WT), *Fcgr3*^*−/−*^ (FcγRIII^−/−^) or SCID (severe combined immune deficiency) mice were treated with a single dose of anti-CD27, and the expression of the activation marker, KLRG1, was monitored on peripheral blood NK cells ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Treatment with anti-CD27 or anti-CD20/CD27 resulted in a ∼20% increase in KLRG1^+^ NK cells compared with controls in WT mice. A similar level of increase was also observed in FcγRIII^−/−^ mice, indicating that NK activation occurred directly via CD27 and not via Fc-FcγR binding (through FcγRIII). Equally, the increase of KLRG1^+^ NK cells in SCID mice indicates that NK activation does not occur indirectly via CD27-mediated T cell activation as T cells are absent in these mice.

To directly investigate the contribution of NK cells to therapy, they were depleted in the BCL~1~ model ([Figure 3](#fig3){ref-type="fig"}F) using appropriate doses and formulations of anti-asialo GM1 ([@bib49]). NK depletion alone did not significantly alter the survival of control or anti-CD20-treated mice. However, there was impairment of survival in the combination-treated mice after NK depletion compared with non-depleted mice. Thus, akin to T cells, anti-CD27 directly activates NK cells, but anti-CD20/CD27 therapy is not entirely dependent on them.

However, when NK and T cells were simultaneously depleted, the therapeutic benefit of adding anti-CD27 to anti-CD20 was abrogated, such that the mice had the same median survival as those treated with anti-CD20 alone (control, 22 days; anti-CD20, 30 days; combination arm with T and NK depletion, 27 days) ([Figure 3](#fig3){ref-type="fig"}G). Thus, the therapeutic efficacy of anti-CD20/CD27 therapy requires either T or NK cells to augment tumor control by anti-CD20 by a hitherto unknown mechanism.

Anti-CD27 Promotes Intratumoral Myeloid Cell Infiltration {#sec3.5}
---------------------------------------------------------

It is recognized that anti-CD20-mediated antibody-dependent cellular phagocytosis (ADCP) is carried out by myeloid cells ([@bib51], [@bib5]). [Figures 2](#fig2){ref-type="fig"}D and 2E show that there is a greater level of B cell depletion when anti-CD27 is combined with anti-CD20 in the Eμ-TCL1 model. We sought to validate these findings in the BCL~1~ model and to examine whether anti-CD27 altered the myeloid compartment. Spleens of BCL~1~-bearing mice were harvested on day 9 or 13 after tumor inoculation, and tumor cells, normal B cells, NK cells, macrophages, monocytes, and neutrophils were enumerated ([Figures 4](#fig4){ref-type="fig"}A--4F). Consistent with observations in the Eμ-TCL1 model, anti-CD20 rapidly depleted malignant and normal B cells while minimal difference was seen in the tumor load between control and anti-CD27-treated mice at these time points ([Figures 4](#fig4){ref-type="fig"}A and 4B). Combined anti-CD20/CD27 therapy was more effective than anti-CD20 alone in depleting B cells, most evidently with normal B cells at day 9 (means, 12.6 × 10^6^ versus 3.8 × 10^6^, anti-CD20 versus combination) ([Figure 4](#fig4){ref-type="fig"}B). We observed a trend toward reduction in splenic NK cells with anti-CD27 and combined anti-CD20/CD27 treatment compared with controls, most noticeably on day 13 ([Figure 4](#fig4){ref-type="fig"}C), which is described following NK activation ([@bib37]).Figure 4The Effect of Anti-CD27 on Intratumoral Myeloid Cells(A--F) BCL~1~-bearing mice were treated as previously described and spleens harvested on days 9 and 13 and examined for tumor (A), normal B cells (B), NK cells (C), macrophages (D), monocytes (E), and neutrophils (F). Graphs n = 6--15 per group, means shown.(G--I) Naive mice were treated as in (A--F) and spleens harvested on day 13 and examined for macrophages (G), monocytes (H), and neutrophils (I) (n = 8--17 per group), means shown.Student's t test (A, C--E, and G) and Wilcoxon test (B, F, H, and I) were used to assess p values; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001.(J) BCL~1~-bearing mice treated as in (A--F) and spleens harvested on day 9 and stained for tumor (BCL~1~), normal B cells (B220), macrophages (F4/80), monocytes (CD14), and neutrophils (Ly6c/Ly6g) by immunohistochemistry. Scale bar represents 500 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Examination of the myeloid compartment in the spleen at the same time points demonstrated no significant changes in macrophage numbers ([Figure 4](#fig4){ref-type="fig"}D) but marked increases in monocytes and neutrophils ([Figures 4](#fig4){ref-type="fig"}E and 4F). There was an 8- to 9-fold increase in numbers of monocytes and a 5- to 7-fold increase in neutrophils in anti-CD27 and combination arms, compared with control and anti-CD20 alone.

A similar trend of increased myeloid cell infiltration was also observed in the spleen when the experiment was repeated in naive non-tumor-bearing mice ([Figures 4](#fig4){ref-type="fig"}G--4I), indicating that these changes are CD27 related and not tumor driven. In this case, macrophage numbers were also significantly elevated in the combination group compared with anti-CD20 alone (means, 2.0 × 10^6^ versus 0.7 × 10^6^, respectively). Monocytes and neutrophils were increased 6- and 7-fold, respectively (combination group versus anti-CD20 alone).

The spleens of BCL~1~-bearing mice were also examined by immunohistochemistry on day 9 ([Figure 4](#fig4){ref-type="fig"}J). At this time point, the tumor burden is still low ([Figure 4](#fig4){ref-type="fig"}A) and the splenic architecture preserved, allowing changes in immune populations to be better appreciated. [Figure 4](#fig4){ref-type="fig"}J shows clear evidence of B cell depletion by anti-CD20 and that this is enhanced by the addition of anti-CD27. Consistent with the flow cytometry data ([Figures 4](#fig4){ref-type="fig"}E and 4F), there was increased monocyte and neutrophil staining in the anti-CD27 and anti-CD20/CD27 groups but no obvious increase in macrophages at this early time point.

Depletion of neutrophils had minimal effect on anti-CD20-mediated B cell depletion ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) and there was no statistically significant impact on the survival of anti-CD20/CD27-treated BCL~1~ mice ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Macrophage depletion was also performed using liposomal-encapsulated clodronate, but depletion of macrophages itself impairs BCL~1~ tumor growth, thus preventing us from assessing the contribution of macrophages to anti-CD20/CD27 therapy ([Figure S3](#mmc1){ref-type="supplementary-material"}D). However, we and others have previously shown that macrophages are the main effectors of anti-CD20-mediated B cell depletion ([@bib33], [@bib5], [@bib48]).

Anti-CD27 Indirectly Promotes Infiltration and Activation of Myeloid Cells {#sec3.6}
--------------------------------------------------------------------------

CD27 is not expressed on macrophages, monocytes, or neutrophils ([Figure S3](#mmc1){ref-type="supplementary-material"}E), ruling out direct activation of these cells by anti-CD27. We hypothesized that, upon activation by anti-CD27, T and NK cells release chemokines and cytokines that attract and activate myeloid cells. To investigate this, naive mice were treated with anti-CD20, anti-CD27, or the combination, and mRNA was isolated from the spleens and analyzed with a chemokine and cytokine gene expression array ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Genes that were significantly upregulated in anti-CD27 and/or combination arms in comparison with the control group are shown in [Figure 5](#fig5){ref-type="fig"}A. We observed increased expression of *Fasl*, *Trail* (*Tnfsf10*), and *Ifng* in mice treated with anti-CD27 ± anti-CD20, supportive of increased T and/or NK cytotoxicity. *Cxcl9*, which is associated with a T~H~1 response, and T cell trafficking ([@bib21], [@bib31]) was also increased, in line with the changes observed in [Figure 3](#fig3){ref-type="fig"}D. Conversely, no significant change was observed in cytokines associated with T~H~2 responses, such as *Il4*, *Il5*, and *Il13* ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Furthermore, chemokines associated with myeloid cell trafficking, such as *Ccl3* and *Ccl4*, were elevated in mice treated with anti-CD20, anti-CD27, and the combination.Figure 5The Effect of Anti-CD27 on Macrophages(A) Naive mice were treated as described in [Figure 2](#fig2){ref-type="fig"}A, spleens were harvested on day 9, and RNA was extracted for cytokine and chemokine profiling. The graph is a summary of the genes that are significantly upregulated over the control sample. Means and 95% confidence interval limits shown.(B) CD86 and MHC class II expression on splenic macrophages in naive mice treated with isotype control or anti-CD27. MFI values are shown. Means are shown, n = 12--16/group.(C) BCL~1~-bearing mice were treated as previously described, and myeloid cells were harvested on day 13 and FcγR expression assessed. The fold change of MFI values over isotype-treated mice are shown. Means are shown, n = 7--11 per group.(D) Tumor-bearing mice treated with isotype control or anti-CD27 mAb therapy as previously described were not depleted (No depletion) or simultaneously depleted of T and NK cells (Depletion). Myeloid cells were harvested on day 13, and FcγR expression was assessed. The fold change of MFI values over isotype-treated mice are shown. Means are shown, n = 7--10 per group.(E) Mice were treated as in (D). Absolute numbers of myeloid cells in the spleen of isotype control, combination treated (No depletion), and combination treated (T and NK depletion) are depicted. Means are shown, n = 7--13 per group.(F) Tumor-bearing mice were treated with isotype control, anti-CD20, anti-CD27, or in combination, with or without an IFNγ-neutralizing mAb. Splenocytes were harvested on day 13, and FcγR expression was examined on macrophages. n = 6--8 per group.(G) Naive mice were treated with an isotype control or anti-CD27, and peritoneal macrophages were harvested on day 13. Macrophages were co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled huCD20 tg B cells opsonized with an isotype control or anti-CD20 for 1 hr, and CFSE and F4/80 double-positive cells were examined. The phagocytic index is shown. Means are shown, n = 12.Wilcoxon test was used to analyze p values in monocytes and neutrophils in (C) and (E--G), and Student's t test for the remaining data; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

It is recognized that macrophages are phenotypically and functionally plastic and have the capacity to both kill tumor and promote its development ([@bib8]), with both types capable of mediating ADCP ([@bib14]). The upregulation of *Ifng* and *Cxcl9* by anti-CD27, and combination therapy ([Figure 5](#fig5){ref-type="fig"}A), indicate that these treatments polarize the macrophages toward an anti-tumor phenotype. Consistent with these data, mice treated with anti-CD27 also upregulate CD86 (2-fold) and major histocompatibility complex (MHC) class II (3-fold) on macrophages ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, in the BCL~1~ tumor microenvironment, anti-CD27 and anti-CD20/CD27 also increased the expression of FcγRIV, a key activatory FcγR involved in mediating ADCP on murine macrophages ([@bib23], [@bib6], [@bib22], [@bib47]) ([Figure 5](#fig5){ref-type="fig"}C). In combination treatment, FcγRIV increased 3-fold compared with anti-CD20-treated mice. No obvious changes were observed in the expression of the other activatory FcγRs, FcγRI, and FcγRIII or the inhibitory FcγR, FcγRII on macrophages. On monocytes, anti-CD27 and combination therapy upregulated all of the FcγRs, but the biggest change was seen with FcγRIV, where there was a 2.5-fold upregulation compared with anti-CD20 ([Figure 5](#fig5){ref-type="fig"}C). On neutrophils, the combination arm upregulated all of the activatory FcγRs (FcγRI, FcγRIII, and FcγRIV) but to a lesser degree than on macrophages and monocytes.

To confirm that myeloid cell activation was occurring indirectly through T and NK cells, both populations were depleted in BCL~1~-bearing mice treated with anti-CD27 therapy ([Figure 5](#fig5){ref-type="fig"}D). In the absence of T and NK cells, all the FcγRs failed to upregulate. Further, the profound infiltration of intratumoral monocytes and neutrophils previously observed ([Figures 4](#fig4){ref-type="fig"}E and 4F) was also abrogated ([Figure 5](#fig5){ref-type="fig"}E).

We further hypothesized that IFNγ released by anti-CD27-activated T and/or NK cells mediated these myeloid changes ([Figure 5](#fig5){ref-type="fig"}F). *In vivo* neutralization of IFNγ in BCL~1~-treated mice also abrogated the upregulation of FcγRIV on macrophages and monocytes ([Figures 5](#fig5){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}B). On neutrophils, the FcγRIV upregulation was attenuated to a lesser extent ([Figure S4](#mmc1){ref-type="supplementary-material"}C). FcγRI upregulation was also reduced on monocytes and neutrophils ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Finally, the neutralization of IFNγ also reduced the infiltration of macrophages in the combination arm but not monocytes or neutrophils ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Altogether, these experiments demonstrate that the upregulation of FcγRIV on myeloid cells is entirely dependent on IFNγ released by anti-CD27-activated T and/or NK cells, and that IFNγ also contributed toward intratumoral macrophage recruitment.

To demonstrate that anti-CD27-activated macrophages have improved ADCP capacity, peritoneal macrophages treated with anti-CD27 *in vivo* were harvested and examined in an *ex vivo* phagocytosis assay. Like splenic macrophages, peritoneal macrophages upregulated FcγRIV ∼3.5-fold following anti-CD27 treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Moreover, anti-CD27-activated macrophages phagocytosed significantly more anti-CD20-opsonized B cells than isotype-control-treated macrophages (5-fold increase in phagocytic index) ([Figures 5](#fig5){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}F).

Single-Cell RNA Gene Expression Profiling of Anti-CD20/CD27 Therapy {#sec3.7}
-------------------------------------------------------------------

To further characterize cell-type-specific changes elicited by anti-CD27 treatment, single-cell RNA sequencing was performed on cells isolated from spleens of BCL~1~-bearing mice (day 13), treated as previously described ([Figures 6](#fig6){ref-type="fig"}A--6E and [S5](#mmc1){ref-type="supplementary-material"}A--S5F). We observed a number of changes consistent with the flow cytometry and qPCR array data. First, there was a striking absence of B cells within the combination arm, when compared with anti-CD20 alone ([Figure 6](#fig6){ref-type="fig"}B), indicative of enhanced B cell depletion with combination therapy. Second, myeloid and effector CD8^+^ T cells were markedly increased in the anti-CD27 and combination arms, as illustrated by the higher cell counts ([Figure 6](#fig6){ref-type="fig"}B) and expression of the proliferation marker, *Mki67* ([Figure S5](#mmc1){ref-type="supplementary-material"}A) in these populations. Chemokines associated with myeloid cell infiltration, specifically *Ccl3* ([Figure 6](#fig6){ref-type="fig"}C), *Ccl4* ([Figure S5](#mmc1){ref-type="supplementary-material"}B), and *Ccl5* ([Figure S5](#mmc1){ref-type="supplementary-material"}C), were upregulated upon anti-CD27 and combination treatment. All three chemokines were primarily expressed in effector CD8^+^ T cells, with lower levels of expression in NK cells. *Cxcl9* was also upregulated in macrophages with anti-CD27 and combination therapy ([Figure S5](#mmc1){ref-type="supplementary-material"}D). The upregulation of *Ifng* ([Figure S5](#mmc1){ref-type="supplementary-material"}E) observed in the qPCR array was also observed here with anti-CD27 and combination therapy, and seen in effector CD8^+^ T cells, with some expression in NK cells. Strong *Fcgr4* expression (the gene encoding FcγRIV) was observed in the granulocyte and macrophage populations ([Figure S5](#mmc1){ref-type="supplementary-material"}F), which also displayed upregulation of interferon response genes, *Ifitm3* and *Isg15* ([Figures 6](#fig6){ref-type="fig"}D and 6E).Figure 6Global Gene Expression Profiling of Anti-CD20 and/or Anti-CD27 Treated BCL~1~-Bearing Mice(A--E) Single cell RNA sequencing was performed on spleens harvested on day 13 from BCL~1~-bearing mice treated as described in [Figure 4](#fig4){ref-type="fig"}. t-Distributed stochastic neighbor embedding (t-SNE) plots are shown, with each point representing a cell. (A) t-SNE plot showing the individual immune effector subsets, assigned according to their top match with the coexpression atlas of the Immunological Genome Project. Each population is denoted by a different color and those marked with an asterisk (^∗^) are proliferating. (B) Data from (A) are subdivided into the different treatment conditions to demonstrate changes in the various subsets. (C) Cells in the various condition groups expressing *Ccl3* (effector CD8^+^ T cells and NK cells) are indicated by the blue and red arrows, respectively. The yellow cells lack expression of *Ccl3*. (D) Upregulation of *Ifitm3* on granulocytes and macrophages is indicated by the black and green arrows, respectively. (E) Upregulation of *Isg15* on granulocytes and macrophages is indicated by the black and green arrows, respectively. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Consistent with the previous results, these data show that anti-CD27 activates CD8^+^ T cells, and to a lesser extent NK cells, to release CCL3, CCL4, and CCL5, which potentially increases myeloid cell infiltration. Activated CD8^+^ T cells release IFNγ, which activates myeloid cells, as demonstrated by increased FcγRIV expression.

Anti-huCD27 mAb Displays Similar Activity {#sec3.8}
-----------------------------------------

To confirm that these findings have relevance for humans, BCL~1~ cells were inoculated into human CD27 transgenic (huCD27 tg) mice ([Figure 7](#fig7){ref-type="fig"}A). In this model, the clinical candidate anti-huCD27 mAb, varlilumab ([@bib54]), was employed. As before, we observed a modest improvement in survival with anti-CD20 alone (median survival 44 days). The therapeutic effect of anti-huCD27 monotherapy was again modest, but when given in combination with anti-CD20, significantly enhanced survival benefit was seen with \>70% of mice treated with the combination surviving \>100 days compared with 0% with either monotherapy.Figure 7*In Vivo* and *In Vitro* Activity of Anti-huCD27(A) BCL~1~-bearing, transplanted huCD27 tg mice were treated as in [Figure 2](#fig2){ref-type="fig"}A and a Kaplan-Meier survival curve generated, n = 10 per group, from two independent experiments.(B--J) BCL~1~-bearing huCD27 tg mice were treated as in (A), and splenocytes were harvested on day 13 and examined for percentages of BCL~1~ tumor (B), normal B cells (C), NK cells (D), CD8^+^ T cells (E), Tregs (F), CD8/Treg ratio (G), macrophages (H), monocytes (I), and neutrophils (J). n = 4--5/group, means are shown.(K--M) FcγR expression of macrophages (K), monocytes (L), and neutrophils (M) of mice treated in (A). n = 4--5/group, means are shown.(N) Human PBMCs were cultured with anti-huCD20, anti-huCD27, anti-hu4-1BB, or an isotype control mAb for 48 hr. Cells were harvested and analyzed by flow cytometry. Percentage of CD14^+^ cells are shown in the graph. Means are shown, n = 15--17 per group.(O) The level of CD14 expression on the monocytes gated from (N) are shown. Means are shown, n = 15--17 per group.(P) Human PBMCs, purified monocytes, purified monocytes, and purified T cells were cultured with an isotype control, or anti-huCD27 for 48 hr. The level of CD14 expression on monocytes is shown. Medians are shown, n = 3/group.Wilcoxon test was used to assess p values for (C, F, H, L, N, and O) and Student's t test was used for the rest of the data; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

In keeping with previous data, we observed enhanced B cell depletion ([Figures 7](#fig7){ref-type="fig"}B and 7C). The proportion of NK cells was similar for all treatment arms ([Figure 7](#fig7){ref-type="fig"}D). An increase in CD8^+^ T cells or Tregs was not observed with anti-CD27 and combination therapy, but overall, there was an increased CD8^+^/Treg ratio in the combination arm compared with the other groups ([Figures 7](#fig7){ref-type="fig"}E--7G). A modest increase in macrophages was observed here in the combination arm (means 0.55 versus 0.92, anti-CD20 versus combination, respectively) and, similar to the WT mouse CD27 model, there was increased infiltration of monocytes and neutrophils (1.8-fold and 1.6-fold, combination versus anti-CD20) ([Figures 7](#fig7){ref-type="fig"}H--7J). Examination of FcγR expression on the myeloid cells also demonstrated upregulation of FcγRIV on macrophages, monocytes, and neutrophils in the combination arm compared with anti-CD20 alone ([Figures 7](#fig7){ref-type="fig"}K--7M). Thus, similar to its mouse counterpart, anti-huCD27 is capable of improving anti-CD20-mediated B cell depletion, and this is associated with increased myeloid infiltration and activation.

Next, we studied the *in vitro* effects of anti-huCD27 on peripheral blood mononuclear cells (PBMCs) derived from healthy human donors ([Figures 7](#fig7){ref-type="fig"}N--7P and [S6](#mmc1){ref-type="supplementary-material"}A--S6F). PBMCs were incubated with anti-huCD20, anti-huCD27, or T cell-stimulating anti-hu4-1BB for 48 hr before analysis by flow cytometry. Cultures treated with anti-huCD27 contained 3-fold more monocytes than cultures treated with the other mAbs ([Figures 7](#fig7){ref-type="fig"}N and [S6](#mmc1){ref-type="supplementary-material"}A) and fewer annexin V^+^CD14^+^ cells (2-fold less) ([Figure S6](#mmc1){ref-type="supplementary-material"}B), suggesting that anti-huCD27 improved monocyte viability. On further examination, the level of CD14 on monocytes was seen to be downregulated \>2-fold after anti-huCD27 treatment ([Figures 7](#fig7){ref-type="fig"}O and [S6](#mmc1){ref-type="supplementary-material"}C), which is recognized to be associated with differentiation into macrophages ([@bib34]). In human PBMCs, CD27 is expressed predominantly on T cells (median 60% CD4^+^ and 91% CD8^+^), a small subset of B cells (24%), and a far smaller number of NK cells (2%), but not monocytes ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6F), thereby suggesting that downregulation of CD14 on monocytes potentially occurs indirectly via anti-huCD27 stimulation of T cells. In support of this, purified monocytes do not downregulate CD14 on anti-huCD27 stimulation (median fluorescence intensity \[MFI\], 7183) ([Figure 7](#fig7){ref-type="fig"}P). Re-addition of purified T cells, but not B cells, resulted in the downregulation of CD14 on monocytes.

Discussion {#sec4}
==========

The success of individual mAbs in cancer therapy suggests that combining them will enhance efficacy. However, it is not yet understood how best to combine these mAbs and which combinations will be effective. Our data demonstrate a way in which an immunostimulatory mAb, anti-CD27, can be used to augment the activity of a direct tumor-targeting mAb (anti-CD20) to elicit experimental cures. Anti-CD20 binds to B cells and mediates ADCP of the mAb-opsonized cells. Addition of anti-CD27 stimulates CD8^+^ T cells and NK cells, inducing the release of CCL3, CCL4, and CCL5, which potentially attract myeloid cells. Stimulation of CD8^+^ T cells, and to a lesser extent NK cells, by anti-CD27 also induces release of IFNγ, which activates macrophages to express more FcγRIV and promotes their inflammatory capacity, thus increasing both the number of macrophages available to perform ADCP and their phagocytic ability.

The superior therapy observed with the anti-CD20/CD27 combination could be a summation of effects as anti-CD27 on its own significantly prolongs the survival of mice in this model. Two lines of evidence indicate that this is not the case. First, the depletion of CD4^+^ and CD8^+^ T cells entirely abrogates anti-CD27 activity, but not combination therapy, signifying that in combination, alternative, synergistic mechanisms of anti-tumor activity come into play. Second, the 4-1BB mAb was also highly effective as monotherapy but did not result in a robust combination effect with anti-CD20 in the BCL~1~ model.

There is ample evidence to support the role of CD27 as a costimulatory receptor on T cells. Humans deficient in CD27 ([@bib53]) or CD70 ([@bib27]) are at risk of lymphoproliferative disorders associated with Epstein-Barr virus (EBV) as a result of reduced proliferation of EBV-specific T cells. Our data demonstrate that anti-CD27 monotherapy is entirely dependent on T cells in the BCL~1~ lymphoma model. Similarly, the anti-huCD27 mAb, varlilumab, is dependent on T cells for therapeutic effects in EG7 lymphoma and CT26 colon carcinoma models ([@bib24]).

Existing literature describing the effects of CD27 stimulation on NK cells is limited ([@bib29], [@bib44]). *In vitro* assays demonstrate that engagement of CD27 by an agonistic mAb induces proliferation and IFNγ secretion of NK cells but without any evidence of direct cytotoxicity ([@bib44]). In a B16cOVA model of anti-CD27 therapy, NK cells were shown to be essential in early tumor control but dispensable when tumor engraftment was established ([@bib38]). Here, *Ifng* upregulation was observed on both T and NK cells with CD27 stimulation by single-cell RNA sequencing, albeit the number of NK cells collected were small, thus reducing our ability to detect changes in NK cells. At the protein level, evidence of direct NK activation by anti-CD27 is supported by the upregulation of KLRG1, which is expressed on mature, fully activated NK cells ([@bib26]). In a pulmonary metastatic colorectal model, KLRG1^+^ NK cells were shown to be crucial in protecting against tumor development in a perforin-dependent manner ([@bib32]). Altogether, these data suggest that anti-CD27 is able to directly stimulate NK cells to enhance cytokine effector function and possibly also direct cytotoxicity. Indeed, when anti-CD20 and anti-CD27 were administered in combination, depletion of both T and NK cells was required to abrogate therapy, indicating that loss of either population can in part be compensated by anti-CD27-mediated activation of the other.

We consistently observed increased infiltration of monocytes and neutrophils in naive and BCL~1~-bearing WT and huCD27 models. Potentially, CCL3, CCL4, and CCL5 released by anti-CD27-stimulated effector CD8^+^ T cells account for the myeloid infiltration but this needs further validation. Either a genetic model deficient for all three chemokines or simultaneous neutralization of these chemokines would be required. Given the redundancy between chemokines and their receptors as well as the numerous effector cells involved here, we hypothesize that these investigations will be complex to interpret. Nonetheless, depletion of T and NK cells effectively abrogated both myeloid cell infiltration and activation, thereby pointing to these cells as the source of myeloid chemo-attractants.

Previous investigations by many different groups have demonstrated that macrophage-mediated ADCP is the main mechanism by which anti-CD20 depletes tumor in syngeneic models ([@bib5], [@bib19], [@bib33], [@bib51]). Further, FcγRI and FcγRIV are the two critical activatory FcγRs involved in macrophage-mediated ADCP ([@bib6], [@bib22], [@bib23], [@bib47]). In our model, upregulation of FcγRIV on macrophages, monocytes, and neutrophils, and FcγRI on monocytes and neutrophils, initially suggests that either of these phagocytic cells or FcγR might lead to enhanced ADCP ability. Further work is required to confirm the contribution of each of these activatory FcγRs to the enhanced phagocytosis. Depletion of neutrophils had no effect on BCL~1~ survival or *in vivo* B cell depletion ability, thus ruling out their contribution. While macrophages may be the critical immediate effectors here, the increased numbers of monocytes might also translate to increased macrophage numbers following subsequent monocyte differentiation in the tissue.

Initially contradictory to these findings are others' observations that tumor-associated macrophages are conventionally associated with poor prognosis across a number of different cancers as they have the capacity to support tumor growth through secretion of immunosuppressive cytokines among other mechanisms (reviewed by [@bib56]). Indeed, we observed that depletion of macrophages slowed the growth of BCL~1~. However, these associations are largely in the setting of chemotherapy as opposed to immunotherapy. In this context, it must be remembered that macrophages are also the key effectors of ADCP, and in follicular lymphoma where rituximab is employed, increased numbers of tumor-associated macrophages predict favorable outcome ([@bib46]). Most significantly, our human *in vitro* data corroborate our murine findings by demonstrating that the anti-huCD27 mAb, varlilumab, promotes monocyte viability and potentially differentiation into macrophages. These effects occur via direct CD8^+^ T cell stimulation as demonstrated by the lack of CD14 downregulation on monocytes with T cell depletion. It is of particular interest that an agonistic mAb to 4-1BB did not produce the same effects, despite being another co-stimulator receptor on T cells. We suspect these differences are due to the fact that CD27 is constitutively expressed, whereas 4-1BB expression requires prior activation.

Based on these data, a phase II, multicenter clinical trial has been initiated in relapsed and/or refractory B cell lymphoma to test the combination of rituximab and varlilumab. Finally, our data indicate that anti-CD27 is also effective in enhancing direct tumor-targeting mAbs beyond anti-CD20, such as anti-gp75 in a melanoma model. We anticipate that anti-CD27 can be used to enhance the effects of other direct-targeting mAbs such as anti-CD38 in myeloma and anti-EGFR in solid tumors, and we are in the process of investigating this.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CD3 PerCP eFluor 710 (17A2)eBioscienceCat. \# 46-0032; RRID: [AB_1834428](nif-antibody:AB_1834428){#intref0010}CD3 FITC (KT3)In-houseN/ACD8a FITC (53-6.7)eBioscienceCat. \# 11-0081; RRID: [AB_464914](nif-antibody:AB_464914){#intref0915}CD44 PE (IM7)eBioscienceCat. \# 12-0441; RRID: [AB_465663](nif-antibody:AB_465663){#intref0020}CD62L APC (MEL-14)eBioscienceCat. \# 17-0621; RRID: [AB_469409](nif-antibody:AB_469409){#intref0925}CD4 FITC (RM4-5)eBioscienceCat. \# 11-0042; RRID: [AB_464898](nif-antibody:AB_464898){#intref0030}CD25 APC (PC61.5)eBioscienceCat. \# 17-0251; RRID: [AB_469365](nif-antibody:AB_469365){#intref0035}FOXP3 PE (NRRF-30)eBioscienceCat. \# 12-4771; RRID: [AB_464895](nif-antibody:AB_464895){#intref0040}CD19 APC (1D3)eBioscienceCat. \# 17-0193; RRID: [AB_1659676](nif-antibody:AB_1659676){#intref0045}BCL1 FITC (Mc10-6A5)In-house ([@bib16])N/ANKp46 PE (29A1.4)eBioscienceCat. \# 12-3351; RRID: [AB_996682](nif-antibody:AB_996682){#intref0050}CD49b PerCP eFluor 810 (DX5)eBioscienceCat. \# 46-5971; RRID: [AB_11149865](nif-antibody:AB_11149865){#intref0055}CD11b e450 (M1/70)eBioscienceCat. \# 48-0112; RRID: [AB_1582237](nif-antibody:AB_1582237){#intref0060}F4/80 Alexa Fluor 647SerotecCat. \# MCA4971647; RRID: [AB_2098198](nif-antibody:AB_2098198){#intref0065}Ly6g PE Cy7 (RB6-8C5)eBioscienceCat. \# 25-5931; RRID: [AB_469662](nif-antibody:AB_469662){#intref0070}Ly6c APC eFluor 780 (HK1.4)eBioscienceCat. \# 47-5932; RRID: [AB_2573992](nif-antibody:AB_2573992){#intref0075}CD27 PE (AT124-1)In-houseN/ACD27 PerCP Cy5.5 (LG.3A10)BDCat. \# 563603FcγR (2.4G2)In-houseN/ACD86 PE (GL1)eBioscienceCat. \# 12-0862; RRID: [AB_465767](nif-antibody:AB_465767){#intref0080}Class II FITC (MS/114.15.2)eBioscienceCat. \# 11-5321; RRID: [AB_465231](nif-antibody:AB_465231){#intref0085}B220 APC (RA3-6B2)eBioscienceCat. \# 17-0452; RRID: [AB_469395](nif-antibody:AB_469395){#intref0090}CD5 PerCP Cy5.5 (53-7.3)eBioscienceCat. \# 45-0051; RRID: [AB_914332](nif-antibody:AB_914332){#intref0095}CD8 (YTS169)In-houseN/ACD4 (GK1.5)In-houseN/AAsialo GM1BiolegendCat. \# 146002; RRID: [AB_2462206](nif-antibody:AB_2462206){#intref0100}CD20 (18B12)In-house ([@bib57])N/ACD27 (AT124-1)In-house ([@bib16])N/AA31 (Mc39-16)In-house ([@bib50])N/AOX40 (OX86)In-house ([@bib2])N/ATIGIT (SAP45-9)In-houseN/A4-1BB (LOB12.3)In-house ([@bib16])N/APD-L1 (10F.9G2)BioXcellCat. \# BE0101; RRID: [AB_10949073](nif-antibody:AB_10949073){#intref0105}PD-1 (RMP1-14)BioXcellCat. \# BE0146; RRID: [AB_10949053](nif-antibody:AB_10949053){#intref0110}CTLA-4 (9D9)BioXcellCat. \# BE0164; RRID: [AB_10949609](nif-antibody:AB_10949609){#intref0115}GITR (DTA-1)BioXcellCat. \# BE0063; RRID: [AB_1107688](nif-antibody:AB_1107688){#intref0120}Ly6g (1A8)BioXcellCat. \# BE0075IFNγ (XMG1.2)BioXcellCat. \# BE0055; RRID: [AB_1107694](nif-antibody:AB_1107694){#intref0125}Gp75Dr. Vidarsson, Sanquin nl ([@bib35])N/AHuCD27 (Varlilumab)Celldex Therapeutics\
([@bib54])N/AHuEGFR (Cetuximab)Southampton General Hospital PharmacyN/AHuCD20 (Rituximab)Southampton General Hospital PharmacyN/AHuCD20 (Ritux m2a)In-house ([@bib4])N/AHuCD37 (WR17)In-house ([@bib4])N/AFcγRI FITC (AT152-9)In-house ([@bib14])N/AFcγRII FITC (AT130-2)In-house ([@bib14])N/AFcγRIII FITC (AT154-2)In-house ([@bib14])N/AFcγRIV FITC (9E9)In-house ([@bib14])N/AHuCD14 Pacific Blue (TuK4)eBioscienceCat. \# MHCD1428; RRID: [AB_10373537](nif-antibody:AB_10373537){#intref0130}HuCD27 PE (O323)eBioscienceCat. \# 12-0279; RRID: [AB_10718236](nif-antibody:AB_10718236){#intref0135}HuCD4 Pacific Blue (OKT4)BiolegendCat. \# 317429; RRID: [AB_1595438](nif-antibody:AB_1595438){#intref0140}HuCD8 V500 (RPA-T8)BD BiosciencesCat. \# 560774; RRID: [AB_1937325](nif-antibody:AB_1937325){#intref0145}HuCD56 APC (NKH1)BiolegendCat. \# 318310; RRID: [AB_604106](nif-antibody:AB_604106){#intref0150}HuCD3 PerCP (SK7)BiolegendCat. \# 344814; RRID: [AB_10639948](nif-antibody:AB_10639948){#intref0155}HuCD19 APC-Cy7 (HIB19)BiolegendCat. \# 302218; RRID: [AB_314248](nif-antibody:AB_314248){#intref0160}**Biological Samples**Bone marrow cells from huCD27 tg miceCelldex TherapeuticsHuCD27 tg**Chemicals, Peptides, and Recombinant Proteins**LymphoprepAxis-ShieldCat. \# 07861Liberase TLSigma AldrichCat. \# 5401020001OCT embedding matrixCellPathCat. \# SMA-0100-00ACTL-Test mediumCTLCat. \# CTLT-010Peroxidase InhibitorThermoFisherCat. \# 35000**Critical Commercial Assays**RT^2^ first strand kitQiagenCat. \# 330401RT^2^ SYBR Green qPCR mastermixQiagenCat. \# 330502RT^2^ profiler PCR array for mouse cytokines and chemokinesQiagenCat. \# 330231HRP-conjugated anti-rat IgG polymerVector LaboratoriesCat. \# PI-9400HematoxylinVector LaboratoriesCat. \# H-3401B cell isolation kit II, humanMiltenyi BiotecCat. \# 130-091-151B cell isolation kit, mouseMiltenyi BiotecCat. \# 130-090-862T cell isolation kit, humanMiltenyi BiotecCat. \# 130-096-535Monocyte isolation kit, humanMiltenyi BiotecCat. \# 130-091-153**Deposited Data**Raw sequencing dataThis paperGEO: [GSE_97037](ncbi-geo:GSE_97037){#intref0165}**Oligonucleotides**Barcoded Bead SeqB: 5' --Bead--Linker-\
TTTTTTTAAGCAGTGGTATCAAC\
GCAGAGTACJJJJJJJJJJJJNNNNNNNN\
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3'ChemGeneN/ATemplate_Switch_Oligo: AAGCAGTGGTATCAACG\
CAGAGTGAATrGrGrGEurogentecN/ASMART PCR primer: AAGCAGTGGTATCAACGCAGAGTEurogentecN/ANew-P5-SMART PCR hybrid oligo: AATGATACGGC\
GACCACCGAGATCTACACGCCT GTCCGCGGAAG\
CAGTGGTATCAACGCAGAGT^∗^A^∗^CEurogentecN/ACustom Read 1 primer: GCCTGTCCGCGGAAGC\
AGTGGTATCAACGCAG AGTACIDTN/A**Experimental Models: Cell Lines**Mouse: BCL~1~In-house ([@bib16])N/AMouse: A31In-house ([@bib16])N/AMouse: Eμ-TCL1Gift from Dr. Egle, Salzburg Cancer Research InstituteN/AMouse: HuCD20 tgIn-house ([@bib4])N/A**Experimental Models: Organisms/Strains**Mouse: BALB/cCharles River LaboratoriesStrain: 028Mouse: CBA/HCharles River LaboratoriesN/AMouse: HuCD27 tg: BALB/c.B6-Tg(hCD27)Celldex TherapeuticsN/AMouse: C57BL/6Charles River LaboratoriesStrain: 027Mouse: SCIDCharles River LaboratoriesStrain: 236Mouse: FcγRIII ^-/-^: BALB/c-*Fcgr3*^*-/-*^Gift from Dr. Verbeek, Leiden University Medical Center ([@bib47])N/A**Software and Algorithms**PrismGraphpadN/ACytobankCytobankN/ASABiosciences PCR Array Data Analysis Web portalQiagenN/ASeurat R packageSatija LabN/ACell B softwareOlympusN/A

Contact for Reagent and Resource Sharing {#sec5.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sean H. Lim (<s.h.lim@soton.ac.uk>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Mice {#sec5.3.1}

BALB/c, CBA/H, C57BL/6 and SCID mice were supplied by Charles River Laboratories and maintained in local facilities. FcγRIII^-/-^ mice ([@bib47]) were backcrossed over 10 generations onto the BALB/c background, and were gifted by Dr. Sjef Verbeek (Leiden University). All mice were fed regular chow, had water freely and were maintained in a conventional facility. SCID mice were maintained in a pathogen-free facility. For all experiments, age-matched (predominantly 8-12-week old) female mice were used. Animal experiments were conducted according to the UK Home Office license guidelines and approved by the University of Southampton Ethical Committee. Animals were randomly assigned into experimental groups and housed together under the same conditions. HuCD27 tg mice ([@bib24]) on BALB/c background were maintained in Celldex animal facilities and used according to the Institutional Animal Care and Use Committees guidelines.

### Cell Lines {#sec5.3.2}

BCL~1~ ([@bib41]) and A31 ([@bib13]) B-cell lymphoma lines originated from female mice and were maintained by passage in BALB/c mice or CBA/H mice, respectively. The age of the source mice are not known. Eμ-TCL1 cells were derived from tumor-bearing Eμ-TCL1 tg mice, gifted from Dr. Egle (Salzburg Cancer Research Institute) following consent from C. Croce and Y. Pekarsky. The cells were sourced from a female mouse aged 204 days old at the time of sacrifice. HuCD20 tg B cells used for the *ex vivo* phagocytosis assay were derived from spleens of male and female huCD20 tg mice, approximately between 8 and 15 weeks of age ([@bib4]). Cell lines have been authenticated by PCR (Eμ-TCL1) and flow cytometry (HuCD20 tg, BCL~1~ and A31).

### Human Samples {#sec5.3.3}

PBMCs were obtained from healthy, anonymized adult volunteers through Southampton National Blood Service after informed consent. As the samples were anonymized, the sex and age of the volunteers are not known. Density gradient centrifugation (Lymphoprep, Axis-Shield) performed within 4 hr. Use of human samples was approved by the East of Scotland Research Ethics Service, in accordance with the Declaration of Helsinki.

Method Details {#sec5.4}
--------------

### Lymphocyte Isolation and Flow Cytometry {#sec5.4.1}

For flow cytometric analysis, cells were suspended in a single cell suspension in staining buffer (PBS with 1% w/v BSA, 0.1% w/v sodium azide). An FcγR-blocking (2.4G2) 20 μg/ml was added for 10 min at RT prior to staining with specific antibodies for 15 min, RT. Red cell lysis was then performed (Invitrogen) for 2-3 min. The cells were then washed twice more and then analyzed directly on fixed with 4% paraformaldehyde before collection on the flow cytometer. The FcγR blocking step was omitted with FcγR expression was being examined. For intracellular staining, the cells were fixed and permeabilized (Ebioscience) for 30 min at RT, before washing twice more and staining for 20 min at RT. After two more washes, cells were collected on the flow cytometer. FACSCalibur or FACSCanto (all from BD Biosciences) were used and with data analyzed using Cytobank (Cytobank).

Peripheral blood and/or spleen suspensions were analyzed for CD8^+^ T subsets (anti-CD3 PerCP eFluor 70, anti-CD8 FITC, anti-CD44 PE, anti-CD62L APC), Tregs (anti-CD3 PerCP eFluor 710, anti-CD4 FITC, anti-CD25 APC, anti-FOXP3 PE), BCL~1~ tumour (anti-CD19 APC, anti-BCL~1~ idiotype FITC), NK cells (anti-CD3 FITC, anti-NKp46 PE, anti-CD49b PerCP eFluor 710) and myeloid cells (anti-CD11b e450, anti-F4/80 Alexa Fluor 647, anti-Ly6g APC e780, anti-Ly6c PE Cy7) and CD27 expression (anti-human CD27 PE, anti-mouse CD27 PE).

To enumerate myeloid cells in the spleen, tissue digestion was performed using Liberase (Sigma Aldrich) after tissue harvest as per manufacturer's protocol. Briefly, harvested tissue was cut into small pieces and treated in Liberase TL for 15 min before mashing into a single cell suspension.

### Tumor Models {#sec5.4.2}

Groups of BALB/c mice (n=5-6) received 10^4^ BCL~1~ or A31 cells intravenously on day 0 followed by anti-CD20 (18B12 mIgG2a, 200 μg) on day 4 and anti-CD27 (AT124-1 rIgG2a, 50-100 μg/injection) from day 5-8 by intraperitoneal injection. Alternatively, BCL~1~-inoculated mice received an alternative immunomodulatory mAb from day 5 onwards as specified in the legends. For the A31 model, mAb therapy was repeated again at the same dose and sequence from day 15-18. The survival of the mice was assessed by regular splenic palpation and through normal humane endpoints. The assessor was blinded to the treatment received by the mice.

1 x 10^7^ Eμ-TCL1 cells were intraperitoneally injected into groups of 6- to 8-week old female C57BL/6 mice and leukemic burden monitored by tail bleeds and CD5/B220 expression through flow cytometry as before ([@bib12]). Animals were treated with anti-CD20 (250 μg) and anti-CD27 (100 μg) 1 day later when more than 10% B220^+^CD5^int^ lymphocytes were present in the blood. Animals were euthanized when humane end points were reached or \>80% of lymphocytes were tumor cells and WBC counts \>5 x 10^7^/ml.

For the study of varlilumab, six-week old female BALB/c recipient mice were irradiated and reconstituted with huCD27 tg bone marrow cells. Eight to 10-weeks after bone marrow transplantation, animals were bled and huCD27 expression inspected by flow cytometry, before implantation with BCL~1~.

### *In Vivo* Cell Depletion and IFNγ Neutralization {#sec5.4.3}

For depletion experiments, mice were treated with YTS169 (CD8 depletion, in house), GK1.5 (CD4 depletion, in house) and asialo-GM1 (NK depletion, BioLegend) at doses of 0.5-1 mg, 1 mg and 10-20 μl per injection, every 5 days, from day -1 to day -16 i.p. For neutrophil depletion, mice were treated with 1A8 (BioXcell) at 0.5 mg/injection, every 3-4 days, from day 1 to day 13. For IFNγ neutralization, tumor-bearing mice were treated with anti-IFNγ (XMG1.2, 250 μg/injection) or an isotype control from day 4 to 13 i.p.

### *Ex Vivo* Phagocytosis Assay {#sec5.4.4}

Naïve mice were treated with an isotype control or anti-CD27 50 μg i.p. from days 1 to 4. Peritoneal macrophages were harvested on day 8 by lavage with ice cold PBS. Cells were washed and FcγRIV expression was examined on the macrophages by flow cytometry using FcγRIV FITC and F4/80 A647. Macrophages were resuspended in complete RPMI and plated in 96-well flat bottom plates (5 x 10^5^ cells per well, 100 μl volume) and rested for at least 6 hours. After resting, non-adherent cells were gently washed off, leaving behind macrophage for as effectors. Here, purified huCD20 tg B cells (Miltenyi Biotec) were labelled ith 5 μM CFSE and opsonized with 10 μg/ml anti-CD20 (Ritux m2a) or an isotype control (WR17 m2a) for 20 min, 4°C. The opsonized targets were then washed once and added to macrophages (2.5 x 10^5^ per well, 100 μl volume) and co-cultured for 1 hr at 37°C. Subsequently, co-cultures stained with F4/80 A647 and washed before analysis by flow cytometry. Phagocytic cells were identified by double positivity for CFSE and F4/80 A647. The phagocytic index was calculated as fold change in increase in phagocytosis seen in anti-CD27 treated group compared to the isotype treated group expressed as 1.

### Bone Marrow Isolation and Reconstitution of Mice {#sec5.4.5}

Eight- to 10-week old female huCD27 tg mice on BALB/c background were sacrificed and hind femora and tibiae were isolated and muscle and soft tissue removed. Isolated bones were trimmed at both ends and bone marrow flushed with in complete RPMI until bones were white. The collected cells were passed through a 70 μm sieve and centrifuged at 1500 rpm. Cells were resuspended in 10% v/v DMSO in fetal calf serum (FCS) and frozen in -80°C overnight before being transferred to liquid nitrogen storage until use.

Six-week old female BALB/c recipient mice were irradiated in split doses of 5 and 4 Gy, a day apart. 2-3 x 10^6^/recipient bone marrow cells were thawed, washed and injected in PBS via tail veins. Recipients were housed in pathogen-free facilities and fed acid water. Eight to 10-weeks after bone marrow transplantation, animals were bled and huCD27 expression inspected by flow cytometry.

### Antibodies {#sec5.4.6}

18B12 mIgG2a (anti-CD20) ([@bib9]) was produced in-house from published patented sequences. Parental 18B12 mIgG1 V regions were combined with mouse IgG2a constant regions ([@bib57]). Ritux m2a (mIgG2a) was generated in the similar fashion ([@bib4]). AT124-1 (anti-CD27) ([@bib16]), Mc39-16 (anti-A31 idiotype) ([@bib50]), Mc10-6A5 (anti-BCL~1~ idiotype) ([@bib17]), OX86 (anti-OX40) ([@bib2]), SAP45-9 (anti-TIGIT), LOB12.3 (anti-4-1BB), YTS169 (anti-CD8), GK1.5 (anti-CD4) were produced from the culture supernatant of hybridoma cells or stably transfected Chinese hamster ovary cells.

### Cytokine and Chemokine Profiling {#sec5.4.7}

The spleens of treated mice were harvested on day 6, snap frozen and RNA purified. RNA was converted to cDNA using the RT^2^ first strand kit (Qiagen) and qPCR performed using RT^2^ SYBR Green qPCR mastermix (Qiagen) and RT^2^ profiler PCR array for mouse cytokines and chemokines (Qiagen) as per manufacturer's protocol. Data analysis was performed using the ΔΔC~T~ method and SABiosciences PCR Array Data Analysis Web portal.

### Single Cell RNA Sequencing {#sec5.4.8}

The spleens of mice treated with isotype controls, anti-CD20 (200 μg, day 1), anti-CD27 (100 μg day 2-5) or in combination were harvested on day 13 and digested with Liberase (Sigma Aldrich). Single-cells (100 cells/ul) and barcoded mRNA-binding micro-particles (100 beads/μl) were suspended in droplets containing cell lysis buffer (∼1nl; 50 cell /μl final concentration). Droplets were then broken and collected by centrifugation and subjected to cDNA synthesis (Maxima H- RTase), introducing the molecule and cell barcode to every transcript from a single cell (termed a 'STAMP'). 800 STAMPs from each condition were then selected for PCR amplification (15 cycles), library preparation (Nextera XT, Illumina) and Illumina sequencing by synthesis using a custom read 1 primer (NextSeq-500 platform; version 2 chemistry - high output setting; 20 bp read 1, 50 bp read 2 and an 8 bp index 1). Species-mixing experiments are routinely performed in our laboratory and have determined that our implementation of the Drop-Seq protocol robustly achieves single-cell encapsulation and captures transcriptomes from single-cells with high specificity (98.5% of cell encapsulation events are single-species; data not shown). Raw sequencing reads were converted to a sorted unmapped BAM file (FastqToSam, Picard bundled in Dropseq-tools v1.0) and filtered to remove all read-pairs with a barcode base quality of \<10. The second read was trimmed at the 5' end to remove any TSO-adapter sequence and at the 3' end to remove polyA tails. Reads were aligned against mouse reference genome (mm10) using STAR aligner (v2.5.0a), then sorted/converted/merged to a BAM with a tag "GE" onto reads for data extraction. The DigitalExpression program (Dropseq-tools v1.0) performed digital counting (DGE) of the mRNA transcripts (unique molecular identifiers to avoid double counting reads/PCR duplicates) and created a DGE matrix (one measurement per gene per cell). Cells expressing less than 300 or more than 3,000 genes were excluded from further analysis. To normalize counts between samples, scaling factors were calculated using a trimmed mean of M-values using edgeR ([@bib39]). Cluster-specific genes were detected using the t-test algorithm in Seurat (Rahul Satija (NA). Seurat: R toolkit for single cell genomics. R package version 1.4.0.) (p \< 1 × 10^-3^ was considered significant). Annotation of the resulting gene lists relative to the coexpression atlas of the Immunological Genome Project ([@bib25]) was performed using the on-line ToppGene suite.

### Immunohistochemistry {#sec5.4.9}

Spleens were harvested on day 9 and embedded in OCT (CellPath) and frozen in isopentane. Eight μm slices were air-dried overnight, fixed in 100% acetone and blocked with 2.5% normal goat serum and stained for BCL~1~ cells (anti-BCL~1~ idiotype), normal B cells (anti-B220), neutrophils (anti-Ly6c/Ly6g), macrophage (anti-F4/80) and monocyte (anti-CD14). Sections were treated with a peroxidase inhibitor (Pierce) for 10 min before incubation with an HRP-conjugated anti-rat IgG polymer for 30 min, followed by 3,3'-diaminobenzidine for 5 min, and counterstained with haematoxylin (all from Vector Laboratories). Images were recorded using a CXK41 inverted microscope equipped with a CC12 color camera, Plan Achromat 4 x 0.25 objective lens and Cell B software (all from Olympus).

### *In Vitro* Human PBMC Based Assays {#sec5.4.10}

PBMCs were cultured using serum-free media (CTL-Test Medium, CTL) supplemented with glutamine (2 mM), pyruvate (1 mM), penicillin, and streptomycin (100 IU/mL) at 37°C in 5% CO~2~. Cells were cultured in a 24-well plate at 1x10^7^ cells/ml (1.5 x10^7^ cells/well) and stimulated with cetuximab and rituximab (both from Southampton General Hospital oncology pharmacy), anti-4-1BB (clone 3/28, in house) or varlilumab (Celldex Therapeutics) at 5 μg/mL for 48 hr. Post culture, PBMCs were labelled with anti-CD14-Pacific Blue (Biolegend) and analyzed on the flow cytometer. To assess viability, annexin-V FITC staining was simultaneously performed.

Monocytes, T cells and B cells were purified using negative magnetic selection as per manufacturer's protocols (Miltenyi Biotec). T cells and B cells were added back monocytes in a ratio of 5:1 and 1:1, respectively. Cells were then culture as described above.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

### Statistical Analysis {#sec5.5.1}

Statistical analysis was performed using Graphpad Prism version 6. Normality was tested using the D'Agostino and Pearson, and Shapiro-Wilk tests, and transformed into logarithmic form to assess for log normal distribution. Subsequently, a two-tailed Student's t test was used to analyze parametric data and non-parametric data was analyzed by a Mann-Whitney test (unpaired data) or Wilcoxon test (paired data). To assess survival differences in immunotherapy experiments, Kaplan-Meier curves were produced and analyzed by log-rank testing. p values \<0.05 were regarded as statistically significant.

Data and Software Availability {#sec5.6}
------------------------------

The accession number for the single cell RNA sequencing data reported in this paper is GEO: [GSE_97037](ncbi-geo:GSE_97037){#interref0010}.
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